AGP Executive Report
Last update: 11 hours agoKidney Disease: A China-run Phase 3 trial found telitacicept largely preserved kidney function over two years in people with IgA nephropathy, with fewer disease-progressions than placebo. The drug received conditional approval in China in June. Hearing Technology: China has approved its first brainstem implant for deafness, a milestone for people who may not benefit from conventional hearing devices. Pain Care: China plans to establish 1,000 county-level chronic pain management centers, expanding access beyond major cities. Health Costs: Medical insurance costs in China are expected to rise 6% in 2027. Elder Care: Chinese care homes are testing intergenerational living, bringing older residents together with younger tenants as the country seeks new ways to support an aging population.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
